Drug intelligence / Profile preview

CS-001

Development stage: Phase 3
Lead developer: Jupiter Wellness
Modality: Small Molecules
Administration: Topical

Overview

CS-001 is a small molecule drug under development as a topical treatment for canities (grey hair). Its mechanism of action involves affecting lysosomal storage and the transfer of melanin from hair follicle melanocytes, which has been shown in vitro and in a small pilot study to induce re-pigmentation of grey hair. The drug is being developed by Applied Biology, with clinical trials underway to assess its safety and efficacy for this indication. The route of administration is topical, and it has not yet received regulatory approval or an FDA designation[1][2].

Beyond the preview

Go deeper on CS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-001.

Explore the full profile